On September 10, SIMCERE PHARMA (02096) extended its share repurchase program, investing approximately HK$14.25 million to buy back 1.265 million shares at prices ranging from HK$11.17 to HK$11.38 per share. This follows the company's previous buyback of 929,000 shares the day prior. The consistent repurchase activity underscores the company's dedication to protecting shareholder interests and its firm belief in long-term value creation.

The company delivered a robust financial performance in the first half of 2026, with total revenue reaching RMB 4.58 billion, a year-on-year increase of 27.8%. Adjusted net profit surged 48.7% to RMB 960 million, while revenue contribution from innovative drugs climbed to 85%, reflecting strong product and R&D capabilities. Additionally, its subsidiary, Simcere Zaiming, has entered into an exclusive licensing agreement with Roche for the global development and commercialization of the CD79a/CD19/CD3 trispecific antibody SIM0660. The deal offers a total transaction value of up to US$1.53 billion, including a US$75 million upfront payment, with potential tiered royalties up to double digits based on future net sales.